Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-CRM immunogenicity and safety study in healthy Russian children, adolescents, and adults
2014-004617-82Phase 3
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal A conjugate vaccine in meningococcal disease, sponsored by Novartis. Primary endpoints: Percentage of subjects with hSBA seroresponse to meningococcal serogroups A, C, W, and Y and Percentage of subjects with hSBA seroresponse by age group.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-004617-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004617-82.